CU20130149A7 - Compuestos de 2-(2,4,5-anilino sustituido)pirimidina - Google Patents
Compuestos de 2-(2,4,5-anilino sustituido)pirimidinaInfo
- Publication number
- CU20130149A7 CU20130149A7 CU2013000149A CU20130149A CU20130149A7 CU 20130149 A7 CU20130149 A7 CU 20130149A7 CU 2013000149 A CU2013000149 A CU 2013000149A CU 20130149 A CU20130149 A CU 20130149A CU 20130149 A7 CU20130149 A7 CU 20130149A7
- Authority
- CU
- Cuba
- Prior art keywords
- compounds
- salts
- pyrimidine
- useful
- mutant
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- HSMPSHPWCOOUJH-UHFFFAOYSA-N anilinyl Chemical class [NH]C1=CC=CC=C1 HSMPSHPWCOOUJH-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 4
- 230000002265 prevention Effects 0.000 abstract 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940116977 epidermal growth factor Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a ciertos compuestos de 2-(2,4,5-anilino sustituido) pirimidina y sales farmacéuticamente aceptables de los mismos que pueden ser útiles en el tratamiento o prevención de una enfermedad o afección mediada por ciertas formas mutadas de receptor del factor de crecimiento epidérmico ( por ejemplo el mutante activo L858R, el mutante activante de la supresión Exon19 y el mutante de resistencia T790M). Tales compuestos y sales de los mismos pueden ser útiles en el tratamiento o prevención de un número de diferentes cánceres. La invención también se refiere a composiciones farmacéuticas que comprenden dichos compuestos y sales de los mismos, especialmente formas polimórficas útiles de estos compuestos y sales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591363P | 2012-01-27 | 2012-01-27 | |
| PCT/GB2012/051783 WO2013014448A1 (en) | 2011-07-27 | 2012-07-25 | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20130149A7 true CU20130149A7 (es) | 2014-04-24 |
Family
ID=52394772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2013000149A CU20130149A7 (es) | 2012-01-27 | 2013-11-14 | Compuestos de 2-(2,4,5-anilino sustituido)pirimidina |
Country Status (2)
| Country | Link |
|---|---|
| CU (1) | CU20130149A7 (es) |
| EA (2) | EA202092034A3 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10237722A1 (de) * | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
| WO2008009458A1 (en) * | 2006-07-21 | 2008-01-24 | Novartis Ag | 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
| SG10201510696RA (en) * | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
| KR101256018B1 (ko) * | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
-
2012
- 2012-07-25 EA EA202092034A patent/EA202092034A3/ru unknown
- 2012-07-25 EA EA201990482A patent/EA036521B1/ru not_active IP Right Cessation
-
2013
- 2013-11-14 CU CU2013000149A patent/CU20130149A7/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA036521B1 (ru) | 2020-11-19 |
| EA202092034A2 (ru) | 2020-12-30 |
| EA201990482A1 (ru) | 2019-07-31 |
| EA202092034A3 (ru) | 2021-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13013033A (es) | Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de egfr útiles para el tratamiento del cáncer | |
| CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
| ZA201800022B (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| MX379110B (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| MX2016009013A (es) | Derivados de heterociclilo biciclicos como inhibores de cinasa-4 asociada al receptor de interleucina-1 (irak4). | |
| PH12014502363A1 (en) | N-aryltriazole compounds as lpar antagonists | |
| PH12016501355B1 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
| PH12014502789A1 (en) | N-alkyltriazole compounds as lpar antagonists | |
| MX2020010674A (es) | Agonistas del receptor muscarinico. | |
| CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| UY34530A (es) | Antagonistas del receptor de vanilloides de potencial transitorio 1 (trpv1) | |
| NI201400134A (es) | Novedosas n - piridinil amidas cíclicas sustituidas como inhibidores de quinasa. | |
| PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| CL2016002267A1 (es) | Ureas asimétricas p-sustituidas y usos médicos de las mismas | |
| CY1123185T1 (el) | Παραγωγα ινδολιου | |
| EA201892529A1 (ru) | Комбинация чистых антагонистов 5-htрецепторов с ингибиторами ацетилхолинэстеразы | |
| MA39450A1 (fr) | Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine | |
| CU20130149A7 (es) | Compuestos de 2-(2,4,5-anilino sustituido)pirimidina | |
| MX378175B (es) | Novedosos compuestos heterocíclicos y su uso tanto en medicina como en cosmética. | |
| UA108954C2 (xx) | Сполуки 2-(2,4,5-заміщеного аніліно)піримідину | |
| CU20140134A7 (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa |